Joseph M Cicchese1, Elsje Pienaar1,2, Denise E Kirschner2, Jennifer J Linderman1. 1. Department of Chemical Engineering, University of Michigan, 2800 Plymouth Rd, NCRC B28, Ann Arbor, MI, 48109-2800. 2. Department of Microbiology and Immunology, University of Michigan Medical School, 1150 W Medical Center Drive, 5641 Medical Science II, Ann Arbor, MI 48109-5620.
Abstract
INTRODUCTION: Tuberculosis (TB), one of the most common infectious diseases, requires treatment with multiple antibiotics taken over at least 6 months. This long treatment often results in poor patient-adherence, which can lead to the emergence of multi-drug resistant TB. New antibiotic treatment strategies are sorely needed. New antibiotics are being developed or repurposed to treat TB, but as there are numerous potential antibiotics, dosing sizes and potential schedules, the regimen design space for new treatments is too large to search exhaustively. Here we propose a method that combines an agent-based multi-scale model capturing TB granuloma formation with algorithms for mathematical optimization to identify optimal TB treatment regimens. METHODS: We define two different single-antibiotic treatments to compare the efficiency and accuracy in predicting optimal treatment regimens of two optimization algorithms: genetic algorithms (GA) and surrogate-assisted optimization through radial basis function (RBF) networks. We also illustrate the use of RBF networks to optimize double-antibiotic treatments. RESULTS: We found that while GAs can locate optimal treatment regimens more accurately, RBF networks provide a more practical strategy to TB treatment optimization with fewer simulations, and successfully estimated optimal double-antibiotic treatment regimens. CONCLUSIONS: Our results indicate surrogate-assisted optimization can locate optimal TB treatment regimens from a larger set of antibiotics, doses and schedules, and could be applied to solve optimization problems in other areas of research using systems biology approaches. Our findings have important implications for the treatment of diseases like TB that have lengthy protocols or for any disease that requires multiple drugs.
INTRODUCTION: Tuberculosis (TB), one of the most common infectious diseases, requires treatment with multiple antibiotics taken over at least 6 months. This long treatment often results in poor patient-adherence, which can lead to the emergence of multi-drug resistant TB. New antibiotic treatment strategies are sorely needed. New antibiotics are being developed or repurposed to treat TB, but as there are numerous potential antibiotics, dosing sizes and potential schedules, the regimen design space for new treatments is too large to search exhaustively. Here we propose a method that combines an agent-based multi-scale model capturing TB granuloma formation with algorithms for mathematical optimization to identify optimal TB treatment regimens. METHODS: We define two different single-antibiotic treatments to compare the efficiency and accuracy in predicting optimal treatment regimens of two optimization algorithms: genetic algorithms (GA) and surrogate-assisted optimization through radial basis function (RBF) networks. We also illustrate the use of RBF networks to optimize double-antibiotic treatments. RESULTS: We found that while GAs can locate optimal treatment regimens more accurately, RBF networks provide a more practical strategy to TB treatment optimization with fewer simulations, and successfully estimated optimal double-antibiotic treatment regimens. CONCLUSIONS: Our results indicate surrogate-assisted optimization can locate optimal TB treatment regimens from a larger set of antibiotics, doses and schedules, and could be applied to solve optimization problems in other areas of research using systems biology approaches. Our findings have important implications for the treatment of diseases like TB that have lengthy protocols or for any disease that requires multiple drugs.
Authors: Philana Ling Lin; Veronique Dartois; Paul J Johnston; Christopher Janssen; Laura Via; Michael B Goodwin; Edwin Klein; Clifton E Barry; Joanne L Flynn Journal: Proc Natl Acad Sci U S A Date: 2012-07-23 Impact factor: 11.205
Authors: Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Kathy Williams; Ian Rosenthal; Richard J O'Brien; Andrew A Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset Journal: Am J Respir Crit Care Med Date: 2004-08-11 Impact factor: 21.405
Authors: Salla A Munro; Simon A Lewin; Helen J Smith; Mark E Engel; Atle Fretheim; Jimmy Volmink Journal: PLoS Med Date: 2007-07-24 Impact factor: 11.069
Authors: G An; B G Fitzpatrick; S Christley; P Federico; A Kanarek; R Miller Neilan; M Oremland; R Salinas; R Laubenbacher; S Lenhart Journal: Bull Math Biol Date: 2016-11-08 Impact factor: 1.758
Authors: Dick Menzies; Andrea Benedetti; Anita Paydar; Ian Martin; Sarah Royce; Madhukar Pai; Andrew Vernon; Christian Lienhardt; William Burman Journal: PLoS Med Date: 2009-09-15 Impact factor: 11.069
Authors: Cristina Curreli; Valentina Di Salvatore; Giulia Russo; Francesco Pappalardo; Marco Viceconti Journal: Ann Biomed Eng Date: 2022-09-17 Impact factor: 4.219